Celltrion Reports Results of Truxima (biosimilar- rituximab) in P-III Study for Advanced Follicular Lymphoma in the US
Shots:
- The P-III study involves assessing of Truxima vs Rituxan in 140 patients with AFL for 40mos. across India- Japan- Russia- and the EU- including Germany and Spain
- The P-III study results: @4yrs. OS (88% vs 93.4%); PFS (60.9% vs 54.7%); TTP (64.2% vs 60.9%)- presented at ASH2019
- Celltrion has launched Truxima in the US via Teva and is the first rituximab biosimilar in the US with an annual sale of $4.2B
Click here to read full press release/ article | Ref: Korea Biomed | Image: Celltrion
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com